Abstract
背景:眼睑痉挛是一种局限性肌张力障碍,患者眼睛周围的肌肉频繁不自主收缩导致眼睑闭合和视力障碍。目前治疗眼睑痉挛的效果并不是很理想。本文是一项右美沙芬对眼睑痉挛疗效的回顾性研究。方法:回顾性研究包括22例特发性眼睑痉挛,患者接受右美沙芬治疗,30mg 每天三次口服,采用扬科维奇评分(Jankovic Rating Scale, JRS)和眼睑痉挛的残疾指数(Blepharospasm Disability Index, BSDI)评价疗效。结果:右美沙芬治疗前基线JRS评分是5.55±1.10分,BSDI基线评分为2.87±0.59。右美沙芬治疗1周后,JRS评分下降到2.82 ± 0.85分,BSDI下降到1.36 ± 0.58分。在接下来的3周的治疗,JRS和BSDI得分保持在一个稳定的状态。停止右美沙芬治疗一周后,JRS评分(5.41 ± 1.01分)和BSDI评分(2.63 ± 0.64分)回到治疗前的基线水平。结论:本研究发现右美沙芬对眼睑痉挛患者有效,这一发现可能意味着另一种治疗选项。 Background: Blepharospasm is a focal dystonia characterized by intermittent or continual invo-luntary contractions of the facial muscles around both eyes. It causes frequent eyelid closure and visual disturbance. The current therapies for blepharospasm are not satisfactory. Here is a retrospective study to analyze the therapeutic effect of dextromethorphan on blepharospasm. Methods: This retrospective study included 22 patients with blepharospasm. They were treated with dextromethorphan, 30 mg orally three times a day for 4 weeks. The effect of dextromethorphan on essential blepharospasm was evaluated using Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI). Results: Before treatment, the baseline JRS score was 5.55 ± 1.10 points, and the BSDI score was 2.87 ± 0.59 points. After 1 week of dextromethorphan treatment, the JRS score decreased to 2.82 ± 0.85 points and the BSDI score to 1.36 ± 0.58 points. In the following 3 weeks of dextromethorphan treatment, the JRS and BSDI scores kept in a steady state. One week after the dextromethorphan treatment, the JRS (5.41 ± 1.01 points) and BSDI (2.63 ± 0.64 points) scores returned to the pre-treatment baseline level. Conclusion: We found that dextromethorphan is effective to relieve the symptoms in patients with blepharospasm, and this finding might imply an alternative treatment option to essential blepharospam.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have